Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
Musto P, Falcone A, Sanpaolo G, Bodenizza C, Perla G, Minervini MM, Cascavilla N, Dell'Olio M, La Sala A, Mantuano S, Melillo L, Nobile M, Scalzulli PR, Bisceglia M, Carella AM.
Musto P, et al. Among authors: scalzulli pr.
Leuk Lymphoma. 2004 Jun;45(6):1219-22. doi: 10.1080/10428190310001641143.
Leuk Lymphoma. 2004.
PMID: 15360005